On April 13, the "China-UAE Business and Investment Promotion Conference", jointly hosted by the Ministry of Commerce of the People's Republic of China and the Ministry of Foreign Trade of the United Arab Emirates, was held in Beijing. The conference brought together ministers, senior government officials, and business leaders from both countries to explore new opportunities for cooperation, investment, and innovation. Eric Tse, Chief Executive Officer of Sino Biopharmaceutical (1177.HK) and Chairman of CTTQ Pharma and Beijing Tide Pharmaceutical, was invited to attend the opening ceremony. 

This conference was held during the official visit of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi, to the People's Republic of China. 

During the China-UAE Business and Investment Promotion Conference, a total of 24 memorandums of understanding were signed between the two countries, further consolidating bilateral economic, trade, and investment cooperation. Dr. Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade, stated at the opening ceremony: "The UAE and China share a long-standing and solid economic partnership, built on decades of cooperation and a shared vision for prosperity".In 2025, the non-oil trade between the two countries exceeded $100 billion for the first time, reaching $111.5 billion, a year-on-year increase of 24.5%. In the future, both sides will continue to deepen cooperation in key areas to promote sustainable economic outcomes that serve the common interests of both countries."

In recent years, as Middle Eastern countries accelerate their economic diversification, the healthcare and biotechnology industries have become key areas of focus. The UAE has identified life sciences and high-end healthcare as key development directions, continuously increasing investment from public finance and industrial funds, promoting the construction of regional healthcare hubs, and actively attracting high-quality global innovation resources. This creates complementary opportunities with China in areas such as innovative drug R&D, industrialization, and market expansion. 

As a significant force in China's pharmaceutical innovation, Sino Biopharmaceutical has in recent years continued to deepen its innovative footprint in key therapeutic areas such as oncology, respiratory/autoimmune diseases, and liver diseases/cardiovascular metabolism. The company is also accelerating the upgrade of its internationalization strategy, actively exploring diverse cooperation models with international pharmaceutical companies and regional partners in R&D, production, and market access to enhance its global resource allocation capabilities. Driven by policy, supported by capital, and propelled by industrial upgrading, Sino Biopharmaceutical will actively seize opportunities in its development, deepen cooperation with the UAE in the life sciences field, and jointly promote the high-quality development of the global health industry. 

Declaration: The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited. 

Source: WAM